The Dotmatics enterprise platform is licensed by Redx Pharma to aid their quest to develop new drug candidates

Tools

The Dotmatics enterprise platform is licensed by Redx Pharma to aid their quest to develop new drug candidates
January 30, 2013

BISHOPS STORTFORD, England--(BUSINESS WIRE)--Dotmatics Limited, a leading provider of informatics services to the pharmaceutical and biotechnology industries, today announced that Redx Pharma have licensed and deployed Dotmatics' entire suite of scientific informatics solutions. This deployment delivers an integrated system that improves access to data, allows the sharing of information and promotes collaboration across different research groups at Redx.

Redx develops new drug candidates across eleven different therapeutic classes using its Redox SwitchTM Platform. The company is undergoing a process of rapid expansion. This constant growth creates a dynamic research environment that requires an informatics platform able to hold increasing amounts of complex and diverse data. In addition, it has to be easy to use and intuitive in order to facilitate the quick and efficient adoption by users. Furthermore, the system has to prevent input errors and it has to be compliant with directives from regulatory authorities.

After extensive testing, the Dotmatics Platform proved to be the most flexible informatics system capable of integrating diverse discovery activities from chemistry to biology. The Dotmatics Platform provides Redx with comprehensive informatics solutions to successfully store, query, manage, visualise and analyse their two hundred families of compounds and all associated data.

Using Studies Notebook, chemists and biologists at Redx easily and securely store their structured and unstructured data in a single web-based system. Scientists are able to access their data faster, aggregate them in a single interface and create custom reports in a productive and efficient manner using Browser. Browser is a scalable and robust query and visualisation tool for biological and chemical datasets alike. Dotmatics' flagship solution Vortex is a world-class visualisation and analytics platform designed specifically to work with scientific data. Vortex provides scientists at Redx with an out-of the-box filtering, charting, plotting and chemically aware calculations engine, enabling scientists to evaluate large datasets in a rich, intuitive and flexible user interface.

Dotmatics CEO, Stephen Gallagher, PhD, said "We are delighted to be working with such a forward thinking organisation as Redx Pharma and we are looking forward to further collaboration with them as both companies continue to develop and move forward."

Dr Neil Murray, CEO of Redx Pharma, said: "Redx is a rapidly growing drug discovery and development company that was looking to install a single informatics platform solution that could address our needs as we grow. "We chose Dotmatics as we felt they provided the best balance of flexibility against range of capability."

About Dotmatics

Dotmatics has rapidly emerged as a preferred informatics supplier to many of the world's largest global Pharmaceutical, Biotechnology and Academic organisations. Dotmatics is a scientific software company deploying web-based knowledge solutions that dramatically improve the way scientific data is queried, managed and shared within companies. Dotmatics has significant expertise in Cheminformatics and Bioinformatics techniques including Chemical databases, SAR analysis, data management and data visualisation. A privately owned company, Dotmatics was founded in 2005 and has its head office based south of Cambridge, UK.

www.dotmatics.com

About Redx Pharma

Redx Pharma is a UK-based pharmaceutical company developing new drug candidates using the broad-based potential of its innovative Redox Switch™ platform. Their novel approach, which has seen validation across 11 different therapeutic classes, has allowed Redx Pharma to generate an enviable pipeline of candidate programs which are characterised by demonstrably lower risk and greater speed into development and providing a flow of licensing opportunities that is filling the global pharma productivity gap.

Contacts

Dotmatics Limited
Dr Mariana Vaschetto
Tel (Europe): +44(0)1279 654 123
Tel (US West Coast): +1 (619) 419 2808
Tel (US East Coast): +1 (781) 281 2330
Fax: +44(0)1279 653 088
Email: sales@dotmatics.com
or
Paver Smith
Ruth Cobban
0151 239 5000
cobban@paversmith.co.uk